Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis.

[1]  T. Tsai,et al.  Etanercept use for psoriasis in Taiwan: a case series study , 2013, International journal of dermatology.

[2]  S. Raychaudhuri.  A Cutting Edge Overview: Psoriatic Disease , 2013, Clinical Reviews in Allergy & Immunology.

[3]  Ryuichi Yamamoto,et al.  The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn's disease complicated by extensive subcutaneous aseptic neutrophilic abscesses. , 2012, Journal of Crohn's & colitis.

[4]  S. Chimenti,et al.  Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target. , 2012, Current pharmaceutical biotechnology.

[5]  E. Berardesca,et al.  Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis , 2012, Immunopharmacology and immunotoxicology.

[6]  É. Estève,et al.  [Psoriasis: a systemic disease]. , 2012, Presse medicale.

[7]  I. Maruyama,et al.  Granulocyte and monocyte adsorption apheresis as an effective treatment for Reiter disease , 2012, Clinical and experimental dermatology.

[8]  É. Estève,et al.  Psoriasis : une maladie systémique , 2012 .

[9]  M. Suárez-Fariñas,et al.  Post-Therapeutic Relapse of Psoriasis after CD11a Blockade Is Associated with T Cells and Inflammatory Myeloid DCs , 2012, PloS one.

[10]  C. Ritchlin.  Strategies for Biomarker Development in Psoriatic Disease: A Report from the GRAPPA 2010 Annual Meeting , 2012, The Journal of Rheumatology.

[11]  G. Zanni.  Psoriasis: issues far more serious than cosmetic. , 2012, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[12]  A. Pietrzak,et al.  Cytokine network in psoriasis revisited. , 2011, European cytokine network.

[13]  K. Okuma,et al.  Granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis , 2011, The Journal of dermatology.

[14]  K. Iwatsuki,et al.  Beneficial effects of neutrophil-targeted therapy for pyoderma gangrenosum associated with ulcerative colitis. , 2011, European journal of dermatology : EJD.

[15]  Y. Okumura,et al.  Generalized Pustular Psoriasis Successfully Treated With Granulocyte and Monocyte Adsorption Apheresis , 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[16]  Takayuki Yamamoto,et al.  Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study , 2011, Journal of Gastroenterology.

[17]  J. Korzenik,et al.  Psoriasis Associated With Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease , 2011 .

[18]  D. Aly,et al.  Serum levels of interleukin‐8, tumor necrosis factor‐α and γ‐interferon in Egyptian psoriatic patients and correlation with disease severity , 2011, The Journal of dermatology.

[19]  M. Eberhardson,et al.  The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review , 2011, Clinical and experimental immunology.

[20]  T. Matsui,et al.  An Open-Label Prospective Randomized Multicenter Study Shows Very Rapid Remission of Ulcerative Colitis by Intensive Granulocyte and Monocyte Adsorptive Apheresis as Compared With Routine Weekly Treatment , 2009, The American Journal of Gastroenterology.

[21]  T. Hibi,et al.  Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[22]  T. Hibi,et al.  Randomized , Double-Blind , Sham-Controlled Study of ranulocyte / Monocyte Apheresis for Active Ulcerative Colitis , 2008 .

[23]  M. Kikuyama,et al.  Adsorptive Depletion of Elevated Proinflammatory CD14+CD16+DR++ Monocytes in Patients With Inflammatory Bowel Disease , 2008, The American Journal of Gastroenterology.

[24]  J. Arenas,et al.  Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis. , 2008, World journal of gastroenterology.

[25]  M. Seishima,et al.  Efficacy of Granulocyte and Monocyte Adsorption Apheresis for Pustular Psoriasis , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[26]  J. Saurat,et al.  Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) , 2007, The British journal of dermatology.

[27]  I. Bjarnason,et al.  Therapeutic leukocytapheresis for inflammatory bowel disease. , 2007, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[28]  Katsuyuki Tozawa,et al.  Demonstration of Low-Regulatory CD25High+CD4+ and High-Pro-inflammatory CD28−CD4+ T-Cell Subsets in Patients with Ulcerative Colitis: Modified by Selective Granulocyte and Monocyte Adsorption Apheresis , 2007, Digestive Diseases and Sciences.

[29]  A. Saniabadi,et al.  Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: Cytokine profiles and endoscopic findings , 2006, Inflammatory bowel diseases.

[30]  I. Maruyama,et al.  Granulocyte and Monocyte Adsorption Apheresis (GCAP) for Refractory Skin Diseases Caused by Activated Neutrophils and Psoriatic Arthritis: Evidence that GCAP Removes Mac‐1‐Expressing Neutrophils , 2006, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[31]  I. Maruyama,et al.  Granulocyte and monocyte adsorption apheresis for leg ulcers in a patient with rheumatoid arthritis. , 2005, Journal of the American Academy of Dermatology.

[32]  M. Gassull,et al.  Granulocyteaphaeresis in steroid‐dependent inflammatory bowel disease: a prospective, open, pilot study , 2004, Alimentary pharmacology & therapeutics.

[33]  Arthur Rook,et al.  Rook's Textbook of Dermatology , 2004 .

[34]  Tatsuo Tanaka,et al.  Correlation of Serum Soluble TNF-α Receptors I and II Levels with Disease Activity in Patients with Ulcerative Colitis , 2004, American Journal of Gastroenterology.

[35]  M. Rybojad,et al.  High frequency of cholestasis in generalized pustular psoriasis: Evidence for neutrophilic involvement of the biliary tract , 2004, Hepatology.

[36]  A. Saniabadi,et al.  Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: Evidence for the involvement of plasma IgG, complement C3 and β2 integrin , 2004, Inflammation Research.

[37]  K. Fukunaga,et al.  Detection of Specific IgE Antibodies to Nafamostat Mesilate as an Indication of Possible Adverse Effects of Leukocytapheresis using Nafamostat Mesilate as Anticoagulant , 2004, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[38]  Katsuhiro Hayashi,et al.  Hepatocyte Growth Factor Facilitates Colonic Mucosal Repair in Experimental Ulcerative Colitis in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.

[39]  T. Tezuka,et al.  Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity , 2003, Archives of Dermatological Research.

[40]  I. Bjarnason,et al.  Adacolumn, an Adsorptive Carrier Based Granulocyte and MonocyteApheresis Device for the Treatment of Inflammatory and RefractoryDiseases Associated with Leukocytes , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[41]  T. Espevik,et al.  The Proinflammatory CD14+CD16+DR++ Monocytes Are a Major Source of TNF1 , 2002, The Journal of Immunology.

[42]  W. Gong,et al.  Expression of CCR6 and CD83 by cytokine-activated human neutrophils. , 2000, Blood.

[43]  H. Tagami,et al.  Role of neutrophils in induction of acute inflammation in T‐cell‐mediated immune dermatosis, psoriasis: A neutrophil‐associated inflammation‐boosting loop , 2000, Experimental dermatology.

[44]  S. Nikolaus,et al.  Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation , 1998, Gut.

[45]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[46]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[47]  R. Thompson,et al.  Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. , 1991, Immunology today.

[48]  S. Allen,et al.  Electron microscopic features in generalized pustular psoriasis. , 1987, The Journal of investigative dermatology.

[49]  G. Lazarus,et al.  Polymorphonuclear leukocytes: possible mechanism of accumulation in psoriasis. , 1977, Science.

[50]  N. Hoede,et al.  [Psoriasis, a systemic disease]. , 1974, Der Internist.

[51]  K. Reich,et al.  Psoriasis--new insights into pathogenesis and treatment. , 2009, Deutsches Arzteblatt international.

[52]  G. Haroske,et al.  Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. , 2008, American journal of clinical dermatology.

[53]  G. Haroske,et al.  Tumor Necrosis Factor-α Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata , 2008 .

[54]  I. Nakamura,et al.  Treatment of pyoderma gangrenosum associated with Crohn's disease , 2003, American Journal of Gastroenterology.

[55]  A. Munakata,et al.  Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: A multicenter study , 2001, Journal of clinical apheresis.

[56]  M. Cassatella.  The production of cytokines by polymorphonuclear neutrophils. , 1995, Immunology today.